For international pharmaceutical companies and investors, the Brazilian market has always been a land of immense promise, albeit one wrapped in regulatory complexity. Recently, this landscape shifted dramatically. The Brazilian Health Regulatory Agency (ANVISA) has just approved five new slimming pens containing semaglutide, signaling a massive surge in demand and a regulatory environment becoming increasingly favorable for foreign players. For global companies looking to capitalize on this trend, understanding the pathways to entry and compliance is critical.<\/p>\n\n\n\n
The approval of five new semaglutide-based injectable medications\u2014Owozy, Seemasun, Zempneo, Semavy, and Orsema\u2014marks a pivotal moment in Brazil’s pharmaceutical sector. These approvals, requested by the Ministry of Health to supply the national market and the public health system (SUS), reflect a profound shift in how obesity and diabetes are treated in the country.<\/p>\n\n\n\n
According to the World Obesity Atlas 2025, for the first time, over 30% of the Brazilian population has obesity, and 68% is at least overweight. With the World Obesity Federation projecting that 48% of adults will suffer from obesity by 2044, the demand for effective treatments like GLP-1 receptor agonists is skyrocketing. Market intelligence from Grand View Research indicates that the Brazil GLP-1 receptor agonist market generated USD 1.02 billion in 2025 and is expected to reach USD 3.19 billion by 2033, growing at a compound annual growth rate (CAGR) of 13.8%.<\/p>\n\n\n\n
The expiration of the Ozempic patent has accelerated the entry of new players, both domestic and international. However, to distribute these lucrative medications, foreign companies must navigate Brazil’s intricate regulatory and corporate framework.<\/p>\n\n\n\n
Entering the Brazilian pharmaceutical market requires strict adherence to local regulations. ANVISA is the primary regulatory body, functioning similarly to the FDA in the United States. Before any medication can be marketed in Brazil, it must undergo a rigorous registration process to prove safety, efficacy, and quality.<\/p>\n\n\n\n
A significant regulatory shift occurred in June 2026 with the enactment of Law No. 15,440\/2026. This law fundamentally changed the registration requirements for imported drugs. Previously, companies had to prove that their products were already registered in their country of origin before applying to ANVISA. Now, this requirement has been removed, allowing global companies to include Brazil in their initial launch strategies rather than treating it as a secondary market.<\/p>\n\n\n\n
However, this does not lower the bar for quality. The new legislation explicitly elevates the requirement for Good Manufacturing Practices (GMP) certification to the legal level. Foreign manufacturers must still demonstrate that their products are produced under robust quality systems that meet internationally accepted standards. Furthermore, the updated reliance framework (ANVISA IN 451\/2026) allows the agency to leverage inspections conducted by trusted foreign authorities, streamlining the approval process without compromising scientific rigor.<\/p>\n\n\n\n
Beyond product registration, foreign pharmaceutical companies must address the corporate and legal requirements of operating in Brazil. A critical hurdle is that foreign entities cannot directly register pharmaceutical products with ANVISA. Brazilian law mandates that a local entity\u2014a Brazilian company or a legal representative\u2014must be legally responsible for drug approvals, imports, distribution, and pharmacovigilance.<\/p>\n\n\n\n
Establishing a local presence typically involves setting up a subsidiary (Sociedade Limitada or Sociedade An\u00f4nima) or a branch. This process requires obtaining a CNPJ (Brazilian corporate tax ID), securing a registered office address, and appointing a local legal representative for non-resident directors. Failure to maintain proper corporate governance and compliance can lead to severe penalties, operational disruptions, and the loss of ANVISA authorizations.<\/p>\n\n\n\n
Moreover, companies must navigate Brazil’s complex tax system, employment laws, and strict anti-corruption regulations (Clean Company Act). Relying on a fragmented approach or attempting to manage these obligations remotely without local expertise often results in costly delays and compliance breaches.<\/p>\n\n\n\n
To successfully capitalize on the booming demand for semaglutide and other innovative therapies in Brazil, foreign investors should adopt a structured, localized approach:<\/p>\n\n\n\n
1.Establish a Robust Local Entity: Forming a Brazilian subsidiary provides the necessary legal framework to hold product licenses, manage imports, and conduct business locally. This requires careful structuring to ensure tax efficiency and compliance with corporate governance standards.<\/p>\n\n\n\n
2.Appoint a Trusted Local Representative: Having a dedicated legal representative in Brazil ensures that the foreign parent company remains informed of all regulatory changes, meets ANVISA requirements, and receives official notifications promptly.<\/p>\n\n\n\n
3.Ensure Seamless Regulatory Alignment: Maintaining open communication between the foreign manufacturing facilities and the local Brazilian entity is crucial for GMP certification and ongoing pharmacovigilance reporting.<\/p>\n\n\n\n
4.Partner with Local Experts: Navigating the Brazilian bureaucracy requires specialized knowledge. Engaging with local advisors who understand both the corporate structuring and the pharmaceutical regulatory landscape is essential for long-term success.<\/p>\n\n\n\n
At PCREPS, we specialize in supporting foreign investors and non-resident directors as they enter and operate in the Brazilian market. Our mission is to make your business journey predictable, secure, and efficient.<\/p>\n\n\n\n
For pharmaceutical companies looking to tap into the lucrative GLP-1 market in Brazil, we provide comprehensive local support. From legal representation for foreign investors and non-resident directors to the administration of subsidiaries and branches, we ensure your corporate structure is fully compliant with Brazilian laws and ANVISA requirements. We also provide registered office addresses and handle the intricate bureaucracy of company registration, CNPJ acquisition, and ongoing administrative compliance.<\/p>\n\n\n\n
By partnering with PCREPS, you gain a trusted local ally that coordinates seamlessly with your global legal, accounting, and regulatory teams, allowing you to focus on what matters most: bringing innovative treatments to the Brazilian market.<\/p>\n\n\n\n
Ready to enter the Brazilian pharmaceutical market with confidence? Contact PCREPS today to learn how we can simplify your market entry and operational setup in Brazil.<\/p>\n\n\n\n
[1] CNN Brasil. “Anvisa aprova cinco novas canetas emagrecedoras de semaglutida.” July 29, 2026.<\/a><\/p>\n\n\n\n [2] Grand View Research. “Brazil Glp-1 Receptor Agonist Market Size & Outlook.”<\/a><\/p>\n\n\n\n [3] World Obesity Federation. “World Obesity Atlas 2025.”<\/a><\/p>\n\n\n\n [4] Halpern, B., & de Melo, M. E. “Obesity in Brazil: 214 million reasons to act.” Archives of Endocrinology and Metabolism, 2026.<\/a><\/p>\n\n\n\n [5] ClarkeModet. “Brazil\u2019s Regulatory Transformation: Why Global Life Sciences Companies Should Enter the Brazilian Market Now.” July 9, 2026.<\/a><\/p>\n\n\n\n [6] TozziniFreire. “Nova lei impacta o registro de medicamentos importados.” June 30, 2026.<\/a><\/p>\n\n\n\n